Has the Veterans Review and Appeal Board, when considering cases from veterans claiming that mefloquine use was a contributing cause of their disability, ever: ( a ) declined to hear further evidence from veterans deployed to Somalia detailing medical problems relating to mefloquine use amongs soldiers; ( b ) declined to recognize that a veteran had suffered a disability related to mefloquine use in either Somalia or Rwanda because it had no evidence from the Canadian Forces showing that the veteran had complained of mefloquine side effects while in Somalia; ( c ) found that mefloquine was not a contributing factor in a disability suffered by a veteran who had been deployed to either Somalia or Rwanda; ( d ) found it had no evidence of mefloquine use by veterans who been deployed to Somalia; ( e ) found it had no evidence of side effects from mefloquine use by veterans who had been deployed to Somalia; ( f ) found it had no evidence to indicate that mefloquine caused emotional problems that would affect decision making capabilities of veterans who had been deployed to Somalia; ( g ) dismissed a claim from a veteran deployed to Somalia on the basis that emotional problems resulting from mefloquine only occur in situations where it is being used in the treatment of malaria and not for the prevention of malaria; ( h ) found it had no evidence to indicate that mefloquine caused suicidal ideation in veterans who had been deployed to Somalia or Rwanda; and in each case, if so, what measures were taken to ensure that the board had received all available data from the Canadian Forces and the Health Protection Branch of Health Canada?
In the House of Commons on November 16th, 1999. See this statement in context.